214 related articles for article (PubMed ID: 28456734)
1. Thermosensitive Gel-Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197.
Fakhari A; Nugent S; Elvecrog J; Vasilakos J; Corcoran M; Tilahun A; Siebenaler K; Sun J; Subramony JA; Schwarz A
J Pharm Sci; 2017 Aug; 106(8):2037-2045. PubMed ID: 28456734
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
3. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.
Siu L; Brody J; Gupta S; Marabelle A; Jimeno A; Munster P; Grilley-Olson J; Rook AH; Hollebecque A; Wong RKS; Welsh JW; Wu Y; Morehouse C; Hamid O; Walcott F; Cooper ZA; Kumar R; Ferté C; Hong DS
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037117
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide.
Dumitru CD; Antonysamy MA; Tomai MA; Lipson KE
Cancer Biol Ther; 2010 Jul; 10(2):155-65. PubMed ID: 20519933
[TBL] [Abstract][Full Text] [Related]
5. In-vivo anti-tumor activity of a novel poloxamer-based thermosensitive in situ gel for sustained delivery of norcantharidin.
Xie MH; Ge M; Peng JB; Jiang XR; Wang DS; Ji LQ; Ying Y; Wang Z
Pharm Dev Technol; 2019 Jun; 24(5):623-629. PubMed ID: 30457414
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of thermosensitive poloxamer 407 gel systems for the sustained release of estradiol in a fish model.
Cespi M; Bonacucina G; Pucciarelli S; Cocci P; Perinelli DR; Casettari L; Illum L; Palmieri GF; Palermo FA; Mosconi G
Eur J Pharm Biopharm; 2014 Nov; 88(3):954-61. PubMed ID: 25194925
[TBL] [Abstract][Full Text] [Related]
7. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.
Dumitru CD; Antonysamy MA; Gorski KS; Johnson DD; Reddy LG; Lutterman JL; Piri MM; Proksch J; McGurran SM; Egging EA; Cochran FR; Lipson KE; Tomai MA; Gullikson GW
Cancer Immunol Immunother; 2009 Apr; 58(4):575-87. PubMed ID: 18791716
[TBL] [Abstract][Full Text] [Related]
8. Combining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.
Seth A; Lee H; Cho MY; Park C; Korm S; Lee JY; Choi I; Lim YT; Hong KS
Oncotarget; 2017 Jan; 8(3):5371-5381. PubMed ID: 28036266
[TBL] [Abstract][Full Text] [Related]
9. Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator.
Lu R; Groer C; Kleindl PA; Moulder KR; Huang A; Hunt JR; Cai S; Aires DJ; Berkland C; Forrest ML
J Control Release; 2019 Jul; 306():165-176. PubMed ID: 31173789
[TBL] [Abstract][Full Text] [Related]
10. Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapy.
Kim H; Sehgal D; Kucaba TA; Ferguson DM; Griffith TS; Panyam J
Nanoscale; 2018 Nov; 10(44):20851-20862. PubMed ID: 30403212
[TBL] [Abstract][Full Text] [Related]
11. Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy.
Muñoz NM; Williams M; Dixon K; Dupuis C; McWatters A; Avritscher R; Manrique SZ; McHugh K; Murthy R; Tam A; Naing A; Patel SP; Leach D; Hartgerink JD; Young S; Prakash P; Hwu P; Sheth RA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589526
[TBL] [Abstract][Full Text] [Related]
12. Assessment of release kinetics, stability and polymer interaction of poloxamer 407-based thermosensitive gel of interleukin-1 receptor antagonist.
Akash MS; Rehman K; Sun H; Chen S
Pharm Dev Technol; 2014 May; 19(3):278-84. PubMed ID: 23506246
[TBL] [Abstract][Full Text] [Related]
13. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity.
Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D
J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
Rostamian M; Niknam HM
Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
[TBL] [Abstract][Full Text] [Related]
15. Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine.
Kim H; Griffith TS; Panyam J
J Pharmacol Exp Ther; 2019 Sep; 370(3):715-724. PubMed ID: 30610006
[TBL] [Abstract][Full Text] [Related]
16. A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner.
Auderset F; Belnoue E; Mastelic-Gavillet B; Lambert PH; Siegrist CA
Front Immunol; 2020; 11():580974. PubMed ID: 33262759
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists.
McGowan DC; Herschke F; Khamlichi MD; Rosauro ML; Benedicto SMP; Pauwels F; Stoops B; Pande V; Scholliers A; Van Schoubroeck B; Mostmans W; Van Dijck K; Thoné T; Horton H; Fanning G; Jonckers THM; Raboisson P
Bioorg Med Chem Lett; 2018 Oct; 28(19):3216-3221. PubMed ID: 30143425
[TBL] [Abstract][Full Text] [Related]
18. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.
Gorski KS; Waller EL; Bjornton-Severson J; Hanten JA; Riter CL; Kieper WC; Gorden KB; Miller JS; Vasilakos JP; Tomai MA; Alkan SS
Int Immunol; 2006 Jul; 18(7):1115-26. PubMed ID: 16728430
[TBL] [Abstract][Full Text] [Related]
19. 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates.
Kasturi SP; Rasheed MAU; Havenar-Daughton C; Pham M; Legere T; Sher ZJ; Kovalenkov Y; Gumber S; Huang JY; Gottardo R; Fulp W; Sato A; Sawant S; Stanfield-Oakley S; Yates N; LaBranche C; Alam SM; Tomaras G; Ferrari G; Montefiori D; Wrammert J; Villinger F; Tomai M; Vasilakos J; Fox CB; Reed SG; Haynes BF; Crotty S; Ahmed R; Pulendran B
Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32561559
[TBL] [Abstract][Full Text] [Related]
20. Thermosensitive micelles-hydrogel hybrid system based on poloxamer 407 for localized delivery of paclitaxel.
Ju C; Sun J; Zi P; Jin X; Zhang C
J Pharm Sci; 2013 Aug; 102(8):2707-17. PubMed ID: 23839931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
